Latest News
-
Wednesday - May 16, 2012
Not intended for U.S. and UK media - 48th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session » more
-
Wednesday - May 16, 2012
LEED Platinum for EcoCommercial Building in India
Bayer building tops global sustainability ranking » more
-
Wednesday - May 16, 2012
Over 25 years of successful collaboration between adidas and Bayer MaterialScience
A tango for the “ball season”
Polyurethanes improve the flight properties of the European championship “Tango 12” soccer ball » more
-
Friday - May 11, 2012
Investment into development capabilities for power generation from renewable sources:
Bayer MaterialScience to establish global wind energy competence center in Denmark
Pooling expertise in research and development » more
-
Thursday - May 10, 2012
Award from the Bayer Cares Foundation for innovative health projects
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care" » more
-
Wednesday - May 9, 2012
Not intended for U.S. and UK media
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome » more
-
Tuesday - May 8, 2012
Greater energy efficiency and safety in road traffic
Bayer MaterialScience develops sustainable solutions for future mobility concepts » more
-
Wednesday - May 2, 2012
Not intended for U.S. and UK media:
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) » more
-
Friday - April 27, 2012
Annual Stockholders' Meeting 2012 » more
-
Thursday - April 26, 2012
1st quarter of 2012:
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed » more
-
Wednesday - April 25, 2012
Not intended for US or UK use - Aesthetic medicine:
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat » more
-
Wednesday - April 25, 2012
Dr. Dirk Ehle appointed Head of Bayer HealthCare's Animal Health Division » more
-
Tuesday - April 24, 2012
Bayer CropScience supports the battle against malaria:
LifeNet™ mosquito nets now available
User-friendly and even effective after 30 washes, providing more nights of protection / Delivery in African countries about to start » more
-
Tuesday - April 24, 2012
Not intended for U.S. and UK media
Bayer expands targeted cancer therapy collaboration with Amgen » more
-
Friday - April 20, 2012
New fungicidal seed treatment product for oilseed rape:
First approval worldwide for EverGol™ in seed treatment
Launch in Canada planned before the end of the year » more
-
Tuesday - April 17, 2012
Bayer MaterialScience at UTECH
April 17 - 19, 2012 in Maastricht » more
-
Tuesday - April 17, 2012
Not intended for U.S. and UK Media: Prevention of Venous Blood Clots after Elective Total Hip or Knee Replacement Surgery:
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
Outcomes from XAMOS study of more than 17,000 orthopaedic surgery patients provide further confirmation of clinical value of rivaroxaban / XAMOS reaffirms robust findings from RECORD – the world’s largest trial programme assessing oral anticoagulation in people requiring hip or knee replacement / Rivaroxaban is the world’s most prescribed new oral anticoagulant in the orthopaedic setting, with almost 2 million patients treated in this indication alone » more
-
Sunday - April 15, 2012
Not intended for U.S. and UK media - Molecular Imaging:
Bayer sells PET tracers to Piramal » more
-
Thursday - April 12, 2012
Agreement for acquisition in the USA:
Bayer will extend polycarbonate sheet business » more
-
Thursday - April 12, 2012
Diabetes Care:
Bayer HealthCare aims to improve diabetes management across borders
“Excellence across Borders” program initiated » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV
